✦ LIBER ✦

PND33 Cost Minimization Analysis of Fingolimod Compared to Natalizumab in Patients with Relapse Remitting Multiple Sclerosis in the Netherlands

✍ Scribed by B. Verheggen; M. Treur; M. Groot

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fingolimod reduces direct medical costs

✍ Heisen, M.; Treur, M. J.; van der Hel, W. S.; Frequin, S. T. F. M.; Groot, M. T. 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 645 KB

PND9 THE COST-EFFECTIVENESS OF NATALIZUM

✍ K Meyer; E Chiao 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PND30 Cost Analysis of Glatiramer Acetat

✍ Sánchez-de la Rosa, R.; Sabater, E.; Casado, M.A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PND35 Belgian Cost-Utility Analysis of G

✍ S. Drieskens; K. Moeremans 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PND38 Cost Minimization Analysis of Fing

✍ Crespo, C.; Izquierdo, G.; García-Ruiz, A.; Granell, M.; Brosa, M. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PND1 A Risk-Benefit Analysis of Natalizu

✍ A.R. Walker; B. Deniz; S.T. Alexopoulos; R. Arnold; D. Bates 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB